TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02380625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib and Erlotinib
Description: Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Irbesartan
Description: Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.

Intervention type: OTHER
Group type: OTHER
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
Study: NCT02656810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Single subcutaneous injection
Study: NCT02428296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
Study: NCT03111290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Cortical Stimulation
Description: A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct Cortical Stimulation Sham
Description: Sham trials where no electric pulse is delivered
Study: NCT02274454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
Study: NCT03298230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REmotely SuPervised Exercise Training
Description: As described in the Arms section.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training
Description: As described in the Arms section.
Study: NCT03785574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
Study: NCT00123032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
Study: NCT02015494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM
Study: NCT02015494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM
Study: NCT00991341

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell units stored <= 10 days
Description: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell units stored >= 21 days
Description: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386
Study: NCT03005509

Intervention type: OTHER
Group type: OTHER
Intervention: TQIM checklist
Description: The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist.
Study: NCT04787406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period.
Study: NCT04421222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386
Study: NCT03420781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily
Study: NCT04433364

Intervention type: OTHER
Intervention: biological samples, questionnaires and interviews
Description: Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth.

Intervention type: OTHER
Intervention: biological samples, questionnaires and interviews
Description: Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth.
Study: NCT02264184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Study: NCT03170011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise using the Biodex Sit2Stand Trainer
Description: Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
Study: NCT03536910

Intervention type: OTHER
Group type: OTHER
Intervention: Copeptin
Description: Level of copeptin in maternal blood and umbilical cord blood

Intervention type: OTHER
Group type: OTHER
Intervention: Copeptin
Description: Level of copeptin in maternal blood and umbilical cord blood
Study: NCT02139098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5 mg capsule zolpidem before going to bed on 8 out of 17 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 5 mg capsule zolpidem before going to bed on 8 out of 17 nights

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 13 out of 17 nights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02920697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 55746
Description: S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 55746
Description: S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
Study: NCT03766256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with pharmacists
Description: Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Study: NCT01843543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Course
Description: The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
Study: NCT00822081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
Description: 1 drop BID in each eye
Study: NCT00908401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: Breastmilk: 0.2 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sucrose
Description: oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
Study: NCT04787406

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period.
Study: NCT03383393

Intervention type: DRUG
Intervention: Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
Description: intracoronary drugs

Intervention type: DRUG
Intervention: Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
Description: intracoronary drugs

Intervention type: DRUG
Intervention: Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
Description: intracoronary drugs
Study: NCT00002583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 50 mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine ditartrate
Description: 25 mg/m2 IV
Study: NCT02867904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg depomedrol, 1ml, injection)
Description: Experimental Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine (4ml 0.5%, injection)
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine (4ml 0.5%, injection)
Description: Control
Study: NCT00907842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietex Parastomal Mesh
Description: mesh placed intraperitoneally around the stoma
Study: NCT00976235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT - Implantable Miniature Telescope
Description: Implantation of the telescope prosthesis (performed under the initial study)
Study: NCT04523558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes
Description: Extended depth of field intraocular lens made form hydrophobic material
Study: NCT03767777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artery Stent Graft System
Description: The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
Study: NCT00886665

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 4 g, powder, oral, 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWHGWT
Description: JWHGWT, 4 g, powder, oral, 3 times a day
Study: NCT04156269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CS1 cCAR T cells
Description: BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.